undamentalytics Newsletter
Sign in

Vivos Therapeutics, Inc. income statement

In fiscal 2025, Vivos Therapeutics, Inc. reported revenue of $17.4m, up 16.0% on the year before, operating income of −$19.9m (a -114.1% margin) and net income of −$21.2m, or −$2.07 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1113171614151721
Cost of revenue—000667—
Gross profit9101310891113
Research and development——00000—
Selling and marketing22652211
General and administrative1616262922182833
Operating income−11−12−20−25−17−11−20−23
Interest expense000———14
Income before tax−11−12−20−24−14−11−21−26
Net income−11−12−20−24−14−11−21−25
Diluted EPS−$2.97−$0.17−$0.12−$3.24−$1.39−$1.11−$2.07−$1.83
Diluted shares (average)4m4m7m7m10m10m10m14m
EBITDA−10−11−20−24−17−11−19−21

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NEPH vs VVOSVVOS vs ZJYLSNOA vs VVOSBDMD vs VVOS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Vivos Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vivos Therapeutics, Inc.